

Unilateral Malignant Leydig Cell Tumor of Testis in a Patient With Contralateral Cryptorchidism

Ioannis Efthimiou,¹ Charalampos Mamoulakis,¹ George Papageorgiou,² Sabbas Kazoulis,¹ Despina Prevedorou,² George Kontogiorgos,³ Ioannis Christoulakis¹

Keywords: testicular neoplasms, leydig cell tumor, cryptorchidism

Urol J. 2009;6:60-2.
www.uj.unrc.ir

INTRODUCTION

Leydig cell tumors (LCTs) are the most common stromal tumors, accounting for 3% of all testicular neoplasms.⁽¹⁾ Approximately, 3% of the LCTs are bilateral.⁽¹⁾ They may be hormonally active, leading to either feminizing or virilizing syndromes. About 10% of them are malignant.⁽¹⁾ The diagnosis of a malignant LCT is not always easy, because no definite histological criteria exist for malignancy. About 20% of the patients present already with metastases, while 40% of them will develop secondary foci within 2 years.^(1,2) Cryptorchidism is a well-established epidemiological risk factor of testicular germ cell cancer; however, data regarding a possible association with sex cord-stromal testicular tumors are scarce.⁽²⁾ Hereby, we present a rare case of unilateral malignant LCT in a

patient with a history of contralateral cryptorchidism.

CASE REPORT

A 72-year-old man presented with a 2-month history of painless left testicular enlargement. In the past, he had undergone orchidopexy of the contralateral testis for cryptorchidism. Physical examination revealed an irregular hard swollen left testis and a small right one. He had no gynecomastia. Tumor markers (α -fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase) were negative for malignancy. Ultrasonography revealed an 11 \times 6-cm nonhomogeneous testicular mass with multiple hypoechoic nodules. Metastases were not evident in the staging investigations.

¹Department of Urology, General Hospital of Chania "Aghios Georgios," Chania, Crete, Greece
²Department of Pathology, General Hospital of Chania "Aghios Georgios," Chania, Crete, Greece
³Department of Pathology, Geniko Kratiko Hospital "G Genimatas," Athens, Greece

Correspondence Author:
Charalampos Mamoulakis, MD,
MSc, PhD, FEBU
Makedonias 17, 15233, Halandri,
Athens, Greece
Tel: +30 6944 568862
E-mail: chmamoul@otenet.gr

Received October 2007
Accepted June 2008




Figure 1. Malignant leydig cell tumor: pronounced nuclear and cellular polymorphism and abnormal mitosis (\times 400).




Figure 2. Tumor cells stained for inhibin A (\times 400).




Figure 3. Immunohistochemical nuclear expression of Ki-67 ($\times 400$).

A left radical orchidectomy was performed. Histopathology of the specimen revealed malignant LCT (Figure 1). Immunohistochemistry was positive for inhibin A (Figure 2) and Ki-67 (Figure 3), and it was negative for pancytokeratin, cytokeratins AE1/AE3, cytokeratins 8/18, epithelial membrane antigen, carcinoembryonic antigen, alpha-fetoprotein, human chorionic gonadotropin, vimentin, CD30, and actin. Postoperative hormone profile revealed hypergonadotropic hypogonadism. The patient was placed on testosterone substitution and retroperitoneal lymph node dissection was suggested, but he declined further surgery.

DISCUSSION

Around 41.7% of the LCTs in adults are diagnosed incidentally on ultrasonography, 29.2% present with a palpable testicular mass, 16.6% with scrotal pain, and 12.5% with gynecomastia.⁽³⁾ Gynecomastia is an unusual manifestation of a malignant LCT and deserves special attention as it may progress to a palpable testicular mass over a 10-year period. Leydig cell tumors in an undescended testis may exhibit only manifestations of endocrinological disorders (gynecomastia, impotence, and loss of libido).

Ultrasonographic findings vary, and hypoechoic nodules with a nonhomogeneous echoic pattern is the most prevalent feature.⁽³⁾ Contrast-enhanced magnetic resonance imaging seems to be superior to ultrasonography.⁽⁴⁾ Histopathological criteria are useful in predicting malignant potential.⁽⁵⁾ In our patient, microscopic features included marked

nuclear atypia and increased mitotic activity without vascular invasion or infiltrating margins. Furthermore, additional value may be gained by DNA aneuploidy and increased expression of Ki-67/MIB-1 and p53,⁽⁵⁾ as in our case in which Ki-67 was expressed in 10% of the malignant cells.

A thorough review of the literature revealed 480 reported LCTs in adults.⁽²⁾ However, only 20 cases were associated with cryptorchidism, indicating a minimal incidence in these patients. Fifteen and 3 unilateral LCTs have been reported in terms of homolateral cryptorchidism (3 intra-abdominal testes) and bilateral cryptorchidism (1 intra-abdominal testis), respectively. A case with bilateral LCTs was reported in a patient with unilateral cryptorchidism.⁽⁶⁾ Finally, a case of unilateral LCT with contralateral undescended testis was reported; however, the malignant potential of the tumor was unclear.⁽⁷⁾ Our case presents the second report of such a rarity.

Molecular studies have shown specific mutations to have a causative role.⁽⁸⁻¹⁰⁾ There is no evidence that undescended testes are prone to develop LCTs. Although testicular dysgenesis syndrome has been associated with testicular germ cell tumors,⁽¹¹⁾ it is unclear whether the same link can be proposed for LCTs. Further studies are needed to clarify this field.

CONFLICT OF INTEREST

None declared.

REFERENCES

1. Cheville JC. Classification and pathology of testicular germ cell and sex cord-stromal tumors. *Urol Clin North Am.* 1999;26:595-609.
2. Albers P, Albrecht W, Algaba F, et al. Guidelines on testicular cancer. European Association of Urology; 2008. p. 23-5.
3. Carmignani L, Salvioni R, Gadda F, et al. Long-term followup and clinical characteristics of testicular Leydig cell tumor: experience with 24 cases. *J Urol.* 2006;176:2040-3.
4. Fernandez GC, Tardaguila F, Rivas C, et al. Case report: MRI in the diagnosis of testicular Leydig cell tumour. *Br J Radiol.* 2004;77:521-4.
5. Cheville JC, Sebo TJ, Lager DJ, Bostwick DG, Farrow GM. Leydig cell tumor of the testis: a clinicopathologic, DNA content, and MIB-1 comparison of nonmetastasizing and metastasizing tumors. *Am J Surg Pathol.* 1998;22:1361-7.

6. Safak M, Adsan O, Baltaci S, Bedük Y. Bilateral Leydig cell tumors with unilateral cryptorchidism. Case report. *Scand J Urol Nephrol.* 1994;28:433-4.
7. Calleja RK, Rice A, Bullock KN. Unilateral Leydig cell tumour associated with a contralateral undescended testis. *BJU Int.* 1999;83:152.
8. Liu G, Duranteau L, Carel JC, Monroe J, Doyle DA, Shenker A. Leydig-cell tumors caused by an activating mutation of the gene encoding the luteinizing hormone receptor. *N Engl J Med.* 1999;341:1731-6.
9. Fragoso MC, Latronico AC, Carvalho FM, et al. Activating mutation of the stimulatory G protein (gsp) as a putative cause of ovarian and testicular human stromal Leydig cell tumors. *J Clin Endocrinol Metab.* 1998;83:2074-8.
10. Carvajal-Carmona LG, Alam NA, Pollard PJ, et al. Adult leydig cell tumors of the testis caused by germline fumarate hydratase mutations. *J Clin Endocrinol Metab.* 2006;91:3071-5.
11. Skakkebaek NE, Holm M, Hoei-Hansen C, Jorgensen N, Rajpert-De Meyts E. Association between testicular dysgenesis syndrome (TDS) and testicular neoplasia: evidence from 20 adult patients with signs of maldevelopment of the testis. *Apmis.* 2003;111:1-9.